Results 131 to 140 of about 27,235 (300)

A recombinant bispecific single‐chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells [PDF]

open access: hybrid, 2004
Joerg Bruenke   +12 more
openalex   +1 more source

We are on the right track for mantle cell lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
Commentary on: Alzahrani et al. Therapeutic advances and gradual improvement in overall survival in mantle cell lymphoma over 4 decades. Br J Haematol 2025 (Online ahead of print). doi: 10.1111/bjh.20239.
Alessia Moioli, Carlo Visco
wiley   +1 more source

Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post‐CAR‐T‐cell therapy

open access: yesBritish Journal of Haematology, EarlyView.
Efficacy of chimeric antigen receptor (CAR) T‐cell therapy depends not only on tumour traits but also on the potency of CAR‐T cells. In clinical practice, the degrees of cell proliferation during CAR‐T‐cell manufacturing vary significantly among individual cases.
Tomoyasu Jo   +10 more
wiley   +1 more source

Non-affinity platform for processing knob-into-hole bispecific antibody

open access: yesBioresources and Bioprocessing
Bispecific antibodies hold significant potential as next-generation biotherapeutics owing to their ability to simultaneously bind to two targets. However, the development of bispecific antibodies as biotherapeutics has been hindered by the high levels of
Xiaoyang Wang   +5 more
doaj   +1 more source

Allogeneic transplantation after failure of chimeric antigen receptor‐T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes

open access: yesBritish Journal of Haematology, EarlyView.
Summary Clinical outcome after chimeric antigen receptor (CAR)‐T‐cell failure in large B‐cell lymphoma (LBCL) is dismal. Allogeneic stem cell transplantation (alloSCT) represents a potentially curative salvage for relapsed/refractory LBCL, although concerns remain regarding its feasibility and safety in patients exposed to CAR‐T and bispecific ...
Angelica Barone   +10 more
wiley   +1 more source

CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Summary Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with ...
Alexandra Dreyzin   +2 more
wiley   +1 more source

130. Targeting of Adenovirus Vectors to Mesothelin Via a Bispecific Antibody Reveals Enhanced Gene Transfer to Human Pancreatic Cancer Cells [PDF]

open access: hybrid, 2004
MA van Geer   +6 more
openalex   +1 more source

Home - About - Disclaimer - Privacy